Skip to main content
. 2019 Oct 1;9(10):2120–2139.

Figure 2.

Figure 2

Effect of GSK343 on SREBP processing. A. HepG2 and PLC5 cells were treated with 0~20 μM GSK343 for 6 h. The whole cell lysates were analyzed by Western blotting. B. HepG2 and PLC5 cells were treated with 20 μM GSK343 for 6 h. The nuclear lysates were analyzed by Western blotting. C. HepG2 and PLC5 cells were treated with 20 μM GSK343 for 6 h. The nuclear lysates were subjected to SREBP1/2 DNA binding activity assay. P < 0.05 (*) or P < 0.01 (**) indicates significant differences between GSK343-treated and untreated cells. D. HepG2 and PLC5 cells were transfected with SREBP1/2 siRNAs for 3 days. The whole cell lysates were analyzed by Western blotting. E. HepG2 and PLC5 cells were transfected with SREBP1/2 siRNAs and then exposed to 10 μM GSK343 for 72 h. Cell viability was measured by MTS assay. P < 0.05 (*) or P < 0.001 (***) indicates significant differences between siRNA-transfected and untransfected cells.